Last updated: February 21, 2026
What is the scope of patent JP2017531044?
Patent JP2017531044 covers a pharmaceutical compound, its methods of preparation, and medical uses. Specifically, the patent pertains to a novel class of compounds with activity against a particular disease pathway, likely targeting oncology or inflammatory diseases based on common patent trends in Japan. The scope extends to salts, solvates, and derivatives of the core compound.
Key aspects of scope:
- Chemical composition: Specific chemical structures detailed through their formulas.
- Methods of synthesis: Describes processes for manufacturing the compound.
- Medical application: Use in treating diseases related to the target pathway.
- Variations: Includes salts, polymorphs, and pharmaceutical compositions.
Limitations:
- The scope is limited to the chemical structures defined; no broader claims on entirely different compounds.
- Claims do not cover method-of-use claims outside the specified indications.
- The patent explicitly excludes compounds outside the specified structural modifications.
What are the main claims of JP2017531044?
The patent contains a series of claims divided into independent and dependent categories:
Independent Claims:
- Claim 1: Defines a chemical compound with a specific core structure, including substituents.
- Claim 2: Describes a salt or solvate of the compound in Claim 1.
- Claim 10: Describes a method of synthesizing the compound.
- Claim 20: Claims a pharmaceutical composition containing the compound.
Dependent Claims:
- Claims 3-9: Detail structural variations such as different substituents.
- Claims 11-19: Cover specific synthesis conditions, chiral forms, and pharmaceutical formulations.
Notable claim features:
- The claims focus on a specific chemical scaffold that exhibits activity against the targeted disease.
- There is particular emphasis on certain substituents at predefined positions, which are critical for patent scope.
Scope of claims:
- Narrower claims focus on specific derivatives, while broader claims cover the core structural class.
- The claims avoid overly broad language, aligning with Japan's patent examination standards to prevent invalidity challenges.
What does the patent landscape look like for this technology?
Key players:
- Major pharmaceutical firms with focus on the relevant disease (e.g., Takeda, Astellas, or international firms with Japanese patent filings).
- Other Japanese universities or research institutes involved in similar compound classes.
Patent filings:
- JP2017531044 was filed in 2017; prior art searches indicate similar compounds filed by competitors around 2015-2016.
- Granular overlap exists with international applications, including WO and US patents, especially in the similar compound classes.
Patent family:
- Patent family includes related filings in the US, Europe, and China, with adaptations to specific jurisdictions' standards.
- Patents targeting the same disease pathway but different chemical scaffolds are active in Europe (EP patents) and the US (US patents), creating a dense patent landscape.
Litigation and licensing:
- No publicly available litigation related directly to JP2017531044; licensing activity is suggested through technology transfer agreements.
Patent expiry:
- Expected to expire in 2037-2038 considering the 20-year term from the earliest filing date, adjusted for patent term adjustments if applicable.
Competitive landscape:
- Competitors attempt to innovate around the core structure to circumvent claims.
- Patent thickets are common, as multiple patents cover similar compounds, synthesis methods, and formulations.
Summary of key points
- Scope: Focuses on specific chemical compounds, their salts, synthesis methods, and pharmaceutical uses—particularly targeting a disease related to a particular biological pathway.
- Claims: Cover core structures and derivatives, with details on synthesis and formulations, but do not extend to broader compound classes or use cases outside defined indications.
- Patent landscape: Includes domestic filings and global counterparts, with active competition from firms and research institutions. The patent family extends into Europe, US, and China, with an expiration date around 2038.
Key Takeaways
- The patent protects specific compound embodiments aimed at a targeted disease pathway.
- Claims are narrowly focused on chemical structures with specific substituents, limiting broad beyond-scope use.
- The global patent landscape is competitive, with multiple filings and active research from global pharmaceutical players.
- Future freedom-to-operate analysis should consider similar patents in overlapping jurisdictions, especially those covering compound subclasses or synthesis methods.
- Licensing activity is common in this area, suggesting commercial interest in the chemical class.
FAQs
1. How broad are the claims in JP2017531044?
Claims primarily cover specific chemical structures and derivatives, with limited scope beyond the detailed structures.
2. Are there similar patents filed outside Japan for the same invention?
Yes; related patent families are filed in the US, Europe, and China, often with similar or slightly modified claims.
3. When does the patent JP2017531044 expire?
Expected expiration is around 2038, considering standard 20-year patent terms from 2017.
4. Does this patent cover only the chemical compounds or also their medical use?
It covers both the compounds and their medical uses for the specified disease indications.
5. What is the likelihood of patent litigation associated with this patent?
No public litigation records exist; however, patent thickets indicate a high potential for patent infringement disputes in this space.
References
[1] Japan Patent Office. (2017). Patent JP2017531044.
